Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy

Background: To evaluate the short-term outcomes of switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study included 18 eyes diagnosed with aflibercept-resistant PCV. All patients were treated with two to four consecutive ranibizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Young-Joon, Kim, Jae-Hui, Kim, Jong-Woo, Kim, Chul-Gu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704610/
https://www.ncbi.nlm.nih.gov/pubmed/34945034
http://dx.doi.org/10.3390/jcm10245739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704610/
https://www.ncbi.nlm.nih.gov/pubmed/34945034
http://dx.doi.org/10.3390/jcm10245739

Ejemplares similares